[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Ohio State University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":684},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,138,0,25,[9,45,80,102,122,149,174,202,228,251,307,335,358,384,430,449,467,490,523,551,569,592,616,644,665],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":30,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100636542","phase-3-delaying-the-onset-of-nearsightedness-until-treatment-donut-clinical-trial-100636542",false,"NCT07567040","Delaying the Onset of Nearsightedness Until Treatment (DONUT) Clinical Trial","DONUT","Inclusion Criteria:\n\n* Refractive Error (cycloplegic autorefraction, spherical equivalent, at least one eye, inclusive) 6 years: -0.74 D to +0.75 D 7 and 8 years: -0.74 D to +0.50 D 9 and 10 years: -0.74 D to +0.25 D 11 years: -0.74 D to plano\n* Neither eye has -0.75 D or more myopia, spherical component\n* Anisometropia: Less than 1.50 D difference between OD and OS, cycloplegic autorefraction, spherical equivalent\n* Astigmatism: Less than 1.50 DC in both eyes by cycloplegic autorefraction\n* Successfully complete run-in period: take at least 90% of unit dose artificial tears for 2 to 4 weeks (# of unit-dose vials used divided by # nights since baseline visit must equal 0.90 or greater)\n\nExclusion Criteria:\n\n* If Visit 2 (randomization visit) is not completed within 4 weeks of the baseline, eligibility visit.\n* Presence of strabismus (intermittent or constant) based on unilateral cover test at distance and near\n* Known allergy to atropine\n* Systemic issues that may affect accommodation or convergence (e.g., multiple sclerosis, myasthenia gravis, Graves ophthalmopathy, diabetes mellitus, Parkinson's disease, Down syndrome, etc.)\n* Ocular disease (e.g., congenital glaucoma, retinal disease, nystagmus, amblyopia, etc.)\n* Ocular surgery (e.g., cataracts, strabismus)\n* Any previous myopia prevention\u002Fcontrol therapy (e.g., atropine, soft contact lenses, orthokeratology, myopia control spectacles, etc.) for more than one month\n* Pregnancy by self-report",true,"ALL","6 Years","11 Years",{"count":22,"type":23},664,"ESTIMATED","INTERVENTIONAL",[26],"PHASE3","The aims of this clinical trial will test whether or not the onset of nearsightedness is delayed in a group of children randomized to nightly drops in 0.05% atropine in both eyes, in comparison to children who receiving nightly placebo drops in both eyes. The primary outcome is the two-year cumulative incidence of nearsightedness. The second aim of this project will determine whether atropine is associated with slower eye growth in children receiving nightly drops of atropine versus placebo.",[29],"Myopia",[31],"prevention","RECRUITING","2026-08-19",{"date":35,"type":36},"2026-08-21","ACTUAL",{"date":38,"type":36},"2026-05-27",{"date":40,"type":23},"2028-05-15",{"name":42,"class":43},"Ohio State University","OTHER",13,{"id":46,"slug":47,"hasResults":12,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":12,"sex":18,"minAge":52,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":24,"phases":55,"briefSummary":57,"conditions":58,"keywords":68,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":79},"100652361","anxiety-skills-study-100652361","NCT07774481","Anxiety Skills Study","Personalizing and Optimizing CBT Skills for Anxiety","Inclusion Criteria:\n\n* Presence of clinically elevated anxiety\n* Living in Ohio\n\nExclusion Criteria:\n\n* No access to a smartphone\n* Presence of conditions that would necessitate alternative care","18 Years",{"count":54,"type":23},600,[56],"NA","The purposes of this study are: (1) to identify baseline predictors of relative success in cognitive, behavioral, and mindfulness-based treatments for anxiety, (2) explore who benefits from a brief, video-based skill training compared to receiving 4 sessions of therapy, and (3) to evaluate how durable these effects are over 1 year.",[59,60,61,62,63,64,65,66,67],"Anxiety","Anxiety Acute","Anxiety Chronic","Anxiety and Mood Disorders","Social Anxiety Disorder","Panic Disorder (With or Without Agoraphobia)","Generalized Anxiety Disorder","Obsessive-Compulsive Disorder","Specific Phobia",[69,70,71],"anxiety","CBT","treatment","2026-08-17",{"date":33,"type":36},{"date":75,"type":36},"2025-10-20",{"date":77,"type":23},"2030-08-31",{"name":42,"class":43},1,{"id":81,"slug":82,"hasResults":12,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":4,"eligibilityCriteria":86,"healthyVolunteers":12,"sex":87,"minAge":52,"maxAge":4,"enrollmentInfo":88,"targetDuration":4,"studyType":24,"phases":90,"briefSummary":91,"conditions":92,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":79},"100652483","restrained-vs-gripping-string-techniques-in-patients-undergoing-cesarean-delivery-100652483","NCT07772219","Restrained vs Gripping String Techniques in Patients Undergoing Cesarean Delivery","A Randomized Controlled Trial (RCT) Comparing Restrained vs Gripping String Techniques on Patients Undergoing Cesarean Delivery","Inclusion Criteria:\n\n* Age ≥18 years to 50 years old\n* Singleton pregnancy\n* Term gestation (≥37 weeks)\n* Spinal or combined spinal-epidural anesthesia planned\n* Scheduled for elective cesarean delivery\n* Ability to provide informed consent in English\n\nExclusion Criteria:\n\n* Not receiving neuraxial anesthesia or not scheduled for cesarean delivery\n* Preeclampsia\n* Documented fetal anomaly\u002Fcongenital malformations\n* Intrauterine growth restriction (IUGR)\n* Unable to provide informed consent in English without interpreting services or personnel\n* Prisoners\n* Elects for skin-to-skin contact prior to suturing","FEMALE",{"count":89,"type":23},272,[56],"This randomized controlled trial will compare two upper-extremity restraint techniques in patients undergoing elective cesarean delivery under neuraxial anesthesia. Participants will be randomly assigned to either standard forearm restraint placement or wrist-level gripping restraint placement. The study will evaluate whether the position of the restraint affects maternal anxiety during and after cesarean delivery. Anxiety will be measured at several perioperative time points using the State-Trait Anxiety Inventory (STAI-6). Secondary outcomes include pain, patient satisfaction, physiological measures such as heart rate and blood pressure, postpartum distress and mood, and restraint-related safety events. The study aims to determine whether wrist-level gripping restraints may reduce anxiety and improve the patient experience compared with standard forearm restraints.",[93,94],"Maternal Anxiety","Cesarean Delivery","2026-08-14",{"date":33,"type":36},{"date":98,"type":36},"2026-07-09",{"date":100,"type":23},"2029-12-31",{"name":42,"class":43},{"id":103,"slug":104,"hasResults":12,"nctId":105,"briefTitle":106,"officialTitle":106,"acronym":4,"eligibilityCriteria":107,"healthyVolunteers":12,"sex":87,"minAge":52,"maxAge":4,"enrollmentInfo":108,"targetDuration":4,"studyType":24,"phases":110,"briefSummary":111,"conditions":112,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":79},"100646280","improving-uroflowmetry-interpretability-evaluating-the-impact-of-patient-reminder-systems-100646280","NCT07692789","Improving Uroflowmetry Interpretability: Evaluating the Impact of Patient Reminder Systems","Inclusion Criteria\n\n1. Age 18 years or older\n2. Sex assigned at birth: Female.\n3. English-speaking\n4. Scheduled to undergo a urodynamics study at the OSU Upper Arlington Outpatient Clinic, OSU New Albany Outpatient Clinic, or OSU Eye and Ear Institute\n5. Ability to access a telephone\n6. Active MyChart account\n7. Ability to provide informed consent\n8. Documented post-residual volume of less than 150 mL\n9. Ability to be reached by telephone after three call attempts\n10. Negative point-of-care urinary tract infection on the day of the scheduled procedure (SOC)\n\nExclusion criteria:\n\n1. Under 18 years of age\n2. Patients with structural causes of urinary retention\u002Fincomplete bladder emptying (defined as a post-void residual \\>150ml) or a positive point-of-care urinary tract infection on the day of the procedure.\n3. Men are excluded as the population of interest is the female urogynecology population in both urology and obstetrics and gynecology.\n4. Patients without access to a telephone or an active MyChart account are excluded because the intervention relies on telephone calls and electronic messaging for delivery of pre-procedure education and reminders.\n5. Individuals who cannot be reached by telephone are excluded because they cannot receive the intervention.\n6. Non-English speaking individuals are excluded because they will not be able to receive the standardized phone call in English and will not be able to complete the informed consent.",{"count":109,"type":23},162,[56],"The purpose of this study is to evaluate the impact of pre-procedure patient reminder systems on patient satisfaction, preparedness, and anxiety among patients undergoing urodynamics studies. The rate of successful procedure completion will be compared between a prospective intervention group and a historical control group to determine whether the intervention improves procedural success and healthcare delivery.",[113,114],"Pelvic Organ Prolapse","Urinary Incontinence","2026-08-13",{"date":72,"type":36},{"date":118,"type":23},"2026-08",{"date":120,"type":23},"2027-12",{"name":42,"class":43},{"id":123,"slug":124,"hasResults":12,"nctId":125,"briefTitle":126,"officialTitle":126,"acronym":127,"eligibilityCriteria":128,"healthyVolunteers":12,"sex":87,"minAge":52,"maxAge":4,"enrollmentInfo":129,"targetDuration":4,"studyType":24,"phases":131,"briefSummary":132,"conditions":133,"keywords":137,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":143,"startDateStruct":144,"completionDateStruct":146,"leadSponsor":148,"locationsCount":79},"100636063","nourish---a-healthcare-community-partnership-to-improve-nutrition-for-optimal-glycemic-control-and-pregnancy-outcomes-with-pregestational-diabetes-100636063","NCT07560813","NOURISH - A Healthcare-community Partnership to Improve Nutrition for Optimal Glycemic Control and Pregnancy Outcomes With Pregestational Diabetes","NOURISH","Inclusion criteria:\n\n* Pregnant with singleton or twin pregnancy\n* Gestational age \\>8+0 to ≤22+6 weeks at enrollment by project EDD\n* Age ≥ 18 years.\n* Type 1 or 2 diabetes.\n* Screen positive for food insecurity based on answering \"Often\" or \"Sometimes\" true to either of the two questions on the USDA Hunger Vital Sign screening questions (within 12 months of enrolling in prenatal care).\n* English or Spanish speaking.\n* Willing to participate in Mid-Ohio Farmacy program and able to provide a home address to which food delivery can be provided by the Mid-Ohio Food Collective.\n* Hemoglobin A1c criteria:\n\n  * If not taking glucagon-line peptide-1 (GLP-1) or sodium-glucose co-transporter 2 (SGLT2) medication within 12 months of enrolling in prenatal care, A1c ≥6.5% during this time period.\n  * If taking GLP-1 or SGLT2 medication within 12 months of enrolling in prenatal care, A1c≥6.5% during the 12 months prior to initiation of these medications.\n\nExclusion Criteria\n\n* Involuntarily confined or detained.\n* Considered as having a diminished decision-making capacity.",{"count":130,"type":23},174,[56],"Nutrition insecurity (inclusive of food insecurity + poor diet quality) is a fundamental social need that must be addressed to improve treatment and health outcomes for high-risk pregnant women with pregestational type 1 and 2 diabetes, poor glucose control, and food insecurity for whom a healthy diet is critical. The NOURISH trial will provide evidence of a scalable, integrated, and theory-based healthcare-community partnership that includes weekly nutritious produce home delivery, monthly clinic-integrated diabetes, nutrition, and culinary group education, and continuous social needs assessment and support to improve glucose control and pregnancy outcomes. Given the increasing burden and devasting consequences of nutrition insecurity among high-risk pregnant women with diabetes and unmet social needs, NOURISH-an innovative and sustainable healthcare-community partnership-will have significant public health benefit.",[134,135,136],"Type 2 Diabetes","Type 1 Diabetes","Pregnancy, High Risk",[138,135,134,139,140,141],"Pregnancy","food insecurity","nutrition insecurity","social determinants of health","2026-08-12",{"date":95,"type":36},{"date":145,"type":36},"2026-07-06",{"date":147,"type":23},"2030-06-30",{"name":42,"class":43},{"id":150,"slug":151,"hasResults":12,"nctId":152,"briefTitle":153,"officialTitle":154,"acronym":155,"eligibilityCriteria":156,"healthyVolunteers":12,"sex":18,"minAge":52,"maxAge":4,"enrollmentInfo":157,"targetDuration":4,"studyType":24,"phases":159,"briefSummary":160,"conditions":161,"keywords":163,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":166,"lastUpdatePostDateStruct":167,"startDateStruct":169,"completionDateStruct":171,"leadSponsor":173,"locationsCount":79},"100605963","spirit-club-chronic-brain-injury-exercise-platform-100605963","NCT07169370","SPIRIT Club Chronic Brain Injury Exercise Platform","SPIRIT Club CBI Pathway: A Novel Streaming Platform for Physical Activity and Wellness Promotion for Chronic Brain Injury Survivors","SPIRITClubCBI","Inclusion Criteria:\n\n* Age 18 years or older with chronic brain injury (CBI)\n* At least 9 months post-injury\n* Is able to able to be able to demonstrate the ability to meet at least one of the following functional mobility scenarios: 1) able to walk with or without an assistive device or with no more than contact guard assist from a caregiver for steadiness checks and proprioceptive support, 2) able to stand up from a chair with no assistance or no more than contact guard assist from a caregiver for steadiness and proprioceptive support, and\u002For 3) able to maintain steady seated balance in a chair or wheelchair and able to lift at least one limb with minimal assist (\\\u003C25%) from a caregiver against gravity\n* Currently exercising less than 60 minutes per week\n* Able to follow simple commands\n* Participant is his\u002Fher own legal authorized representative (LAR) or LAR is able to verify they can follow simple commands and participate in study and support consenting and participation processes\n* Provides confirmation of medical clearance from physician to participate in moderate levels of activity without supervision from a licensed healthcare provider\n\nExclusion Criteria:\n\n* Unsafe independent functional mobility observed during the functional mobility screen and no available caregiver\u002Fcarepartner to facilitate participation in the study and provide assistance while using the SPIRIT Club platform\n* Being advised by any healthcare provider to avoid or restrict participation in moderate to high-intensity physical activity\n* Uncontrolled blood pressure, unstable angina, severe joint disease, uncontrolled or untreated dizziness or vertigo, or other medical issue precluding exercises leading to lack of clearance from a physician\n* \\- e.g.,\n* Unable to follow simple commands or persistent post-traumatic amnesia\n* Presence of expressive aphasia\n* Lack of fluency in English\n* Unable to follow simple commands or persistent post-traumatic amnesia\n* Regular participation (2 or more days per week) in a structured fitness program or platform (e.g., group exercise classes or personal training)\n* Regular participation (average of 1 or more days per week) in physical therapy services specifically for brain injury rehabilitation",{"count":158,"type":23},60,[56],"Many physical fitness centers and online exercise programs are not designed to support people with intellectual and developmental disabilities. To address this, the investigators are collaborating with SPIRIT Club, a company specializing in fitness for people with disabilities, to improve their platform. The goal is to create a new section of the platform specifically for people with chronic brain injury (CBI). The investigators will test and refine this new section to see how well it works for people with CBI in real-life situations. The research will focus on conducting a study with 60 people who have CBI to see if the new section helps them be more active and confident in their ability to exercise. Half will use the new section, and the other half will just be monitored for their activity. The investigators includes experts in fitness and rehabilitation for people with disabilities from industry, clinical settings, and research.",[162],"Chronic Brain Injury",[164,165],"fitness platform","chronic brain injury","2026-08-03",{"date":168,"type":36},"2026-08-04",{"date":170,"type":36},"2025-11-11",{"date":172,"type":23},"2027-12-01",{"name":42,"class":43},{"id":175,"slug":176,"hasResults":12,"nctId":177,"briefTitle":178,"officialTitle":179,"acronym":4,"eligibilityCriteria":180,"healthyVolunteers":17,"sex":18,"minAge":52,"maxAge":4,"enrollmentInfo":181,"targetDuration":4,"studyType":24,"phases":183,"briefSummary":184,"conditions":185,"keywords":189,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":194,"lastUpdatePostDateStruct":195,"startDateStruct":197,"completionDateStruct":199,"leadSponsor":201,"locationsCount":79},"100611333","the-impact-of-irrisept-in-reducing-urinary-tract-infection-during-urethral-catheter-removal-100611333","NCT07239219","The Impact of Irrisept in Reducing Urinary Tract Infection During Urethral Catheter Removal.","To Determine the Efficacy of Irrisept in Reducing Urinary Tract Infection During Urethral Catheter Removal.","Inclusion Criteria:\n\n1. Presenting to the urology clinic for catheter removal\n2. Must be 18 years or older.\n3. The patient must be able to understand and willing to provide informed consent as described in this study protocol.\n4. Must be willing to complete a post-catheter removal survey\n\nExclusion Criteria:\n\n1. Allergy or adverse reaction to chlorohexidine gluconate\n2. Under the age of 18\n3. Refuse to provide informed consent\n4. On antibiotic therapy for any indication.\n5. Women who are pregnant or breastfeeding\n6. Signs of skin or systemic infection\n7. Patients undergoing catheter exchange",{"count":182,"type":23},300,[56],"Given the high burden of post-catheter removal UTIs, this study aims to evaluate Irrisept instillation as a non-antibiotic intervention to reduce infection rates. By comparing Irrisept to saline irrigation, the study will provide critical insights into the efficacy of antiseptic bladder irrigation in preventing UTIs while minimizing antibiotic use. If successful, this approach could lead to new clinical guidelines for catheter removal protocols, improving patient outcomes and reducing healthcare costs.",[186,187,188],"Urinary Tract Infection","Antibiotic","Catheter Infection",[190,191,192,193],"UTI","antibiotic","Catheter infection","CAUTI","2026-07-30",{"date":196,"type":36},"2026-07-31",{"date":198,"type":36},"2026-01-01",{"date":200,"type":23},"2028-01-01",{"name":42,"class":43},{"id":203,"slug":204,"hasResults":12,"nctId":205,"briefTitle":206,"officialTitle":206,"acronym":4,"eligibilityCriteria":207,"healthyVolunteers":12,"sex":18,"minAge":52,"maxAge":208,"enrollmentInfo":209,"targetDuration":4,"studyType":24,"phases":211,"briefSummary":212,"conditions":213,"keywords":215,"overallStatus":219,"whyStopped":4,"lastUpdateSubmitDate":220,"lastUpdatePostDateStruct":221,"startDateStruct":223,"completionDateStruct":225,"leadSponsor":227,"locationsCount":79},"100649271","augmented-depression-therapy-adept-case-series-100649271","NCT07733310","Augmented Depression Therapy (ADepT) Case Series","Inclusion Criteria:\n\n1. Aged 18 -65\n2. Currently experiencing a major depressive episode based on the Quick Structured Clinical Interview for DSM-5 Disorders (QuickSCID-5; First \\& Williams, 2021)\n3. Scoring \\> 10 on the PHQ-9\n4. Have sufficient knowledge of written and spoken English to provide consent and utilize therapy resources and take assessment measures throughout the protocol without the assistance of a translator.\n\nExclusion Criteria:\n\n1. Diagnosis of a psychotic or bipolar disorder\n2. History of learning disabilities or organic brain change (e.g., from injury or from neurological disorders)\n3. Active alcohol or substance use disorder or level of use that would interfere with ability to engage in ADepT treatment\n4. Current marked risk to self (self-harm or suicidal ideation) that cannot be managed safely within the ADepT treatment frame\n5. Patients cannot be enrolled while they are currently receiving psychotherapy from a different provider in line with current clinic policy and APA ethical guidelines. The possibility of switching providers\u002Ftreatments will be addressed following established departmental policies and procedures, transcranial magnetic stimulation, ketamine, esketamine, or electroconvulsive therapy. Patients receiving a stable dose of an antidepressant agent will be considered eligible.\n6. Presence of another psychiatric disorder judged to be primary","65 Years",{"count":210,"type":23},40,[56],"This research study plans to examine the use of Augmented Depression Therapy (ADepT) in order to evaluate what patients think about ADepT and how well it works. ADepT is a type of therapy that builds wellbeing and is being provided to you as standard of care.\n\nADepT treatment consists of 15 therapy sessions (typically provided weekly) with each session lasting around 60 minutes. Following these sessions, you can receive five optional booster sessions over the next 12 months with each of these lasting around 60 minutes. Ultimately, the timing and duration of these sessions will be determined between you and your provider and scheduled accordingly.\n\nAs part of this study you will be randomized (randomly assigned) to different research assessment lengths before the start of treatment and then will complete assessments for the 12 months following the end of the weekly portion of ADepT treatment. The length of your participation will be between 70 weeks to 82 weeks.",[214],"Depression \u002F Major Depressive Disorder",[216,217,218],"Depression","Major Depressive Disorder","Major Depressive Episode","NOT_YET_RECRUITING","2026-07-28",{"date":222,"type":36},"2026-07-29",{"date":224,"type":23},"2026-08-01",{"date":226,"type":23},"2028-12-31",{"name":42,"class":43},{"id":229,"slug":230,"hasResults":12,"nctId":231,"briefTitle":232,"officialTitle":233,"acronym":4,"eligibilityCriteria":234,"healthyVolunteers":12,"sex":18,"minAge":235,"maxAge":236,"enrollmentInfo":237,"targetDuration":4,"studyType":239,"phases":4,"briefSummary":240,"conditions":241,"keywords":4,"overallStatus":219,"whyStopped":4,"lastUpdateSubmitDate":244,"lastUpdatePostDateStruct":245,"startDateStruct":246,"completionDateStruct":248,"leadSponsor":250,"locationsCount":79},"100628998","serum-inflammatory-protein-concentration-during-dental-treatment-100628998","NCT07468929","Serum Inflammatory Protein Concentration During Dental Treatment","Systemic Molecular Markers of Surgical Trauma in Periodontitis\u002FPeri-implantitis Patients","Inclusion Criteria:\n\n* Adults 21-75 years of age\n* Systemically healthy\n* Non-smoker\n* scheduled to receive nonsurgical or surgical periodontal treatment under IV sedation\n\nExclusion Criteria:\n\n* Patients who have localized form of the disease (less than 30% of available tooth\u002Fimplant sites are affected with the disease)\n* Non-english speaking individuals since informed consent form will be in English only.\n* Patients with uncontrolled systemic diseases (such as metabolic diseases, obesity, diabetes, high blood pressure) since these types of chronic inflammatory challenges would cause increase levels of circulatory serum pro-inflammatory markers.\n* Pregnant patients (pregnancy will be reported by the patient) since pregnancy itself would affect circulatory serum pro-inflammatory markers.\n* Patients who are not willing to have blood drawing for the study purpose.\n* Patients who are not willing to sign research related consent form.","21 Years","75 Years",{"count":238,"type":23},30,"OBSERVATIONAL","The goal of this observational study is to study the molecular markers of stress in blood samples from people who are having periodontal surgery. The main question it aims to answer are:\n\n* How do the levels of inflammatory molecules in the blood change during a periodontal surgery?\n* How are the levels of inflammatory molecules in a person having surgery different from the levels in a person having a nonsurgical procedure?\n* Participants will be people who are having a periodontal surgery or a nonsurgical periodontal treatment as part of their dental care. Participants will be asked to let the investigator take blood samples from them before, during, and after the procedure is being done. The blood will later be analyzed for substances in the blood that are associated with inflammation.",[242,243],"Periodontal Disease","Periodontal Surgery","2026-07-25",{"date":220,"type":36},{"date":247,"type":23},"2026-07",{"date":249,"type":23},"2027-02",{"name":42,"class":43},{"id":252,"slug":253,"hasResults":12,"nctId":254,"briefTitle":255,"officialTitle":255,"acronym":4,"eligibilityCriteria":256,"healthyVolunteers":12,"sex":18,"minAge":52,"maxAge":4,"enrollmentInfo":257,"targetDuration":258,"studyType":239,"phases":4,"briefSummary":259,"conditions":260,"keywords":263,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":299,"lastUpdatePostDateStruct":300,"startDateStruct":302,"completionDateStruct":304,"leadSponsor":306,"locationsCount":79},"100645611","determination-of-resistance-training-status-for-patients-on-glucagon-like-peptide-1-receptor-agonists-100645611","NCT07702461","Determination of Resistance Training Status for Patients on Glucagon-Like Peptide-1 Receptor Agonists","Inclusion Criteria:\n\n* Adult aged 18 years or older\n* Currently taking a GLP-1 receptor agonist medication\n* On the GLP-1 receptor agonist for at least 3 months\n* Using the GLP-1 receptor agonist for type 2 diabetes, overweight or obesity, and\u002For weight management (self-reported)\n* Stable GLP-1 receptor agonist dose for the past 4 to 8 weeks\n* Able to read and respond to the survey in English\n* Willing and able to provide informed consent electronically\n\nExclusion Criteria:\n\n* Currently or planning to become pregnant\n* Planned bariatric surgery within the next 3 months\n* Recent bariatric surgery (within the past 3 months) or other conditions that substantially alter resistance training capacity (e.g., advanced cancer cachexia, severe mobility-limiting conditions)\n* Unable to read or respond to the survey in English",{"count":182,"type":23},"1 Day","This study examines how adults who take a GLP-1 receptor agonist medication (such as semaglutide \\[Ozempic, Wegovy, Rybelsus\\], liraglutide \\[Saxenda, Victoza\\], or tirzepatide \\[Mounjaro, Zepbound\\]) perform resistance (strength) training before and after starting their medication.\n\nGLP-1 medications are being prescribed more and more often to help people manage type 2 diabetes and lose weight. These medications work well, but a known side effect is that people can lose lean (muscle) tissue along with fat. Losing muscle can make it harder to move, do everyday tasks, and stay strong as we age. Resistance training, things like lifting weights, using resistance bands, or doing push-ups and squats, is the most effective way to keep and build muscle. Yet most adults in the United States do not meet the recommended amount of resistance training, and very little is known about the resistance training habits of people who take GLP-1 medications.\n\nThe purpose of this research is to systematically collect information from adults using GLP-1 medications so we can better understand: how often they do resistance training before and after starting the medication; what their sessions look like (frequency, duration, intensity, muscle groups); whether their resistance training is linked to how strong they feel and how well they can carry out daily activities; and what makes resistance training easier or harder while on a GLP-1 medication.\n\nFindings will help doctors, dietitians, exercise professionals, and researchers design better guidance and interventions to protect muscle mass, physical function, and quality of life in people using GLP-1 medications.\n\nWho can join: Adults 18 years or older who are currently taking a GLP-1 receptor agonist medication for type 2 diabetes, overweight or obesity, or weight management, and who have been on the medication for at least three months at a stable dose. Participants must be able to read and respond to the survey in English. People who are pregnant or planning bariatric surgery within the next three months are not eligible.\n\nWhat participants will do: The study is a single, anonymous, online survey. Interested individuals click the survey link, review a short consent page, and indicate their willingness to participate. Eligible participants then answer questions about their background, current health, GLP-1 medication and dose, resistance training habits before and after starting the medication, self-reported strength and function, and things that make resistance training easier or harder. There are no in-person visits, no exercise tests, and no blood draws.\n\nHow long it takes: About 10 minutes total, in one online session. There is no follow-up after the survey and no compensation is offered.\n\nData privacy: The survey is anonymous. No names, email addresses, or IP addresses are collected or linked to responses. The survey runs on Qualtrics, a secure, institution-approved platform hosted on Ohio State University servers.\n\nThe research team hopes to enroll up to 200-300 adults across the United States.",[261,262],"Obesity & Overweight","Diabetes (DM)",[264,265,266,267,268,269,270,271,272,273,274,275,276,277,278,279,280,281,282,283,284,285,286,287,288,289,290,291,292,293,294,295,296,297,298],"GLP-1","GLP-1 Receptor Agonist","GLP-1RA","Semaglutide","Liraglutide","Tirzepatide","Ozempic","Wegovy","Rybelsus","Mounjaro","Zepbound","Saxenda","Victoza","Muscle-strenghtening Exercise","MSEQ","Lean body mass","Sarcopenia","Muscle Preservation","Weight Loss","Weight Management","Resistance Training","Strength Training","Weightlifting","Exercise","Physical Activity","Body weight exercise","Pilates","Holistic Exercise","Physical Function","Activities of Daily Living","Quality of Life","Health Related Quality of Life","Glucagon-Like Peptide-1","Glucagon-Like Peptide-1 Receptor Agonist","Weight Loss Medication","2026-07-23",{"date":301,"type":36},"2026-07-24",{"date":303,"type":36},"2026-06-12",{"date":305,"type":23},"2027-01",{"name":42,"class":43},{"id":308,"slug":309,"hasResults":12,"nctId":310,"briefTitle":311,"officialTitle":312,"acronym":4,"eligibilityCriteria":313,"healthyVolunteers":12,"sex":18,"minAge":52,"maxAge":314,"enrollmentInfo":315,"targetDuration":4,"studyType":24,"phases":317,"briefSummary":318,"conditions":319,"keywords":323,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":330,"lastUpdatePostDateStruct":331,"startDateStruct":332,"completionDateStruct":333,"leadSponsor":334,"locationsCount":79},"100648586","self-supervised-constraint-induced-movement-therapy-for-stroke-recovery-100648586","NCT07723300","Self-Supervised Constraint-Induced Movement Therapy for Stroke Recovery","A Novel Approach to Implementing Constraint-Induced Movement Therapy in Stroke Rehabilitation","Inclusion Criteria:\n\n* Sustained a first-time ischemic or hemorrhagic stroke ≥2 weeks prior to study enrollment\n* Age ≥18 and ≤85\n* Moderate UE hemiparesis as defined by a score ≥13 and ≤47 on the modified UE section of the Fugl-Meyer Assessment (60-point scale with no reflex testing)\n* Ability to actively extend impaired wrist ≥10 degrees\n* UE strength and active range of motion within functional limits on the non-hemiparetic side\n* Ability to follow two-step commands (visual or verbal) as determined by the clinical investigator\n* Nonuse of the more impaired UE as evidenced by an average score ≤2.5 on the Motor Activity Log Amount of Use Scale.\n\nExclusion Criteria:\n\n* Excessive pain in the affected shoulder, arm, or hand as measured by a score ≥6 on a 10-point visual analogue scale\n* Unable to passively reach neutral position for wrist extension and forearm supination\n* Excessive spasticity in the affected wrist or finger flexors\u002Fextensors and elbow flexors, as defined as a score of \\>2 on the Modified Ashworth Scale (MAS)\n* Inability to actively participate in regular therapy sessions (e.g., due to medical complexity, insufficient endurance, transportation, etc.) as determined by participant or by clinical judgement of the evaluating therapist\n* Receiving occupational therapy services for the hemiparetic UE during the two-week intervention window (including after pre-assessment and before post-assessment)\n* Received focal anti-spasticity drug injection (e.g., Botox) to any muscles of the impaired UE within the past 1 month (or plan to at some point during study enrollment)\n* Comorbid diagnosis in addition to stroke (e.g., dementia, peripheral neuropathy) that in the opinion of the investigator could impact study results\n* Presence of moderate to severe unilateral spatial neglect as indicated by clinical observation or failure on a standardized screening tool (e.g., Line Bisection Test or Bells Test).","85 Years",{"count":316,"type":23},12,[56],"The goal of this clinical trial is to learn how a partially self-supervised constraint-induced movement therapy (sCIMT) program in adults with arm and hand weakness will work after stroke. This study will look at whether the program can help people improve the use of their arm and hand after a stroke while requiring less time with a therapist. The main questions it aims to answer are:\n\n* Does the sCIMT program help people use their affected arm and hand better - after a stroke?\n* Do participants feel that the sCIMT program is useful, easy to follow, and a good fit for their recovery needs?\n* Does taking part in the sCIMT program improve participants' quality of life and daily well-being?\n\nParticipants will:\n\n* Take part in a therapy program 5x\u002Fweek for 2 weeks. The program is designed to help improve the use of the arm and hand affected by stroke.\n* Wear a mitt on the stronger hand during certain practice activities to encourage use of the weaker hand.\n* Complete surveys and tests before and after the program to measure arm and hand use, experiences with the program, and quality of life.",[320,321,322],"Stroke","Stroke (CVA) or TIA","Cerebral Vascular Accident (CVA)\u002FStroke",[320,324,325,326,327,328,329],"Constraint-Induced Movement Therapy","Rehabilitation","CIMT","Upper Extremity Rehabilitation","Neurorehabilitation","Post-Stroke Recovery","2026-07-22",{"date":299,"type":36},{"date":247,"type":23},{"date":120,"type":23},{"name":42,"class":43},{"id":336,"slug":337,"hasResults":12,"nctId":338,"briefTitle":339,"officialTitle":340,"acronym":4,"eligibilityCriteria":341,"healthyVolunteers":12,"sex":18,"minAge":52,"maxAge":342,"enrollmentInfo":343,"targetDuration":4,"studyType":24,"phases":345,"briefSummary":346,"conditions":347,"keywords":349,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":330,"lastUpdatePostDateStruct":352,"startDateStruct":353,"completionDateStruct":355,"leadSponsor":357,"locationsCount":79},"100522355","ketogenic-diet-vs-mixed-diet-in-patients-with-heart-failure-100522355","NCT06081543","Ketogenic Diet vs Mixed Diet in Patients With Heart Failure","A Prospective Randomized Unblinded Study of Ketogenetic Versus Mixed Diet on Exercise Tolerance in Subjects With the Metabolic Phenotype of Heart Failure With Preserved Ejection Fraction","Inclusions:\n\n1. Age ≥ 18 years old and ≤ 80 years old \\& willingness to be randomized to either diet.\n2. NYHA class I - III for at least 3 months.\n3. Ejection fraction ≥40% by biplane 2D, or 3D echo, or CMR\n4. Echo findings of abnormal or indeterminant diastolic function or right heart catheterization (RHC) data: At rest: mean pulmonary capillary wedge pressure (PCWP) \\> 15 mmHg. pulmonary vascular resistance (PVR) \\\u003C 3 Wood Units.\n5. Stable medical therapy for at least 3 months as determined by the treating physician (no new cardiac or diabetic medications within 3 months of enrollment or during enrollment and dosage should be stable for 1 month prior to enrollment).\n6. Dose of oral diuretics changes allowed but must be stable for 1 week prior to randomization.\n7. Body Mass Index (BMI) ≥ 25 or Type 2 Diabetes Mellitus or prediabetes (fasting glucose of 100 - 125 mg\u002FdL or glycated hemoglobin (A1C) 5.7-6.4% or metabolic syndrome.\n8. Ability to participate in exercise treadmill testing.\n9. Ability to sign written consent.\n\nExclusions:\n\n1. Women who are pregnant, current breast-feeding, or have intention to become pregnant while in the study.\n2. Known allergy or sensitivity to gadolinium-based contrast agents.\n3. Implanted pacemaker, cardioverter defibrillator, Cardiac resynchronization therapy, left ventricular assist device.\n4. Other metallic implants\u002Faneurysm clips that are contraindicated in MRI.\n5. Claustrophobia\n6. History of severe kidney disease of estimated glomerular filtration rate (eGFR) \\\u003C30 ml\u002Fkg\u002F1.73m2.\n7. Type I diabetes.\n8. History of diabetic ketoacidosis.\n9. Prior diagnosis of oxygen dependent pulmonary disease.\n10. Body Mass Index (BMI) \\\u003C 25.\n11. Recent acute myocardial infarction or acute coronary syndrome (30 days).\n12. Or recent (within 30 days) or planned (within 30 days) cardiac revascularization History of left main disease, severe triple vessel disease, coronary artery bypass graft surgery.\n13. Left ventricular ejection fraction \\\u003C 50%.\n14. Uncontrolled systemic systolic blood pressure (SBP)\u002Fdiastolic blood pressure (DBP) hypertension (SBP \\>180 or DBP \\>110 mmHg).\n15. Severe stenotic or regurgitant valvular heart disease, expected to lead to surgery during the study period.\n16. Persistent atrial fibrillation.\n17. History of uncontrolled or untreated ventricular arrhythmias.\n18. Cardiovascular diseases or treatments that increase the unpredictability of or change the subject's clinical course, independent of heart failure.\n19. Heart transplant or listing for heart transplant.\n20. Cardiomyopathy based on infiltrative diseases (e.g. amyloidosis), accumulation diseases (e.g. haemochromatosis, Fabry disease), muscular dystrophies, cardiomyopathy with reversible causes (e.g. stress cardiomyopathy), hypertrophic obstructive cardiomyopathy or known pericardial constriction.\n21. Acute decompensated heart failure requiring intravenous diuretics, vasodilators, inotropic agents or mechanical support within 1 week of screening and during the screening period prior to randomization.\n22. Hemoglobin of \\\u003C9 g\u002FdL at screening.\n23. Major surgery (major according to the investigator's assessment) performed within 90 days prior to screening, or major scheduled elective surgery (e.g. hip replacement) within 90 days after screening.\n24. Acute or chronic liver disease, defined by serum levels of transaminases or alkaline phosphatase more than three times the upper limit of normal at screening.\n25. Gastrointestinal surgery or gastrointestinal disorder that might interfere with diet. Prior bariatric surgery allowed if weight-stable for past 3 months.\n26. Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of the uterine cervix, or low-risk prostate cancer (subjects with pre-treatment prostate-specific antigen levels of \\\u003C10 ng\u002FmL, and biopsy Gleason scores of ≤6 and clinical stage T1c or T2a).\n27. Presence of any disease other than heart failure that results in a life expectancy of \\\u003C1 year (in the opinion of the investigator).\n28. History or recurrent severe hypokalemia, potassium \\\u003C 3.0 mg\u002FdL.\n29. Current enrollment or completion within 30 days of an investigational device or drug study.\n30. Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, will make the subject unlikely to fulfill the study requirements or complete the trial.\n31. Any other clinical condition that might jeopardize subject safety during participation in this study or prevent the subject from adhering to the study protocol.\n32. Unable or unwilling to follow guidelines of assigned diet group, including inability to purchase food.\n33. Unable to participate in the comprehensive diet program, including biometric data acquisition and data entry.\n34. The subject cannot currently be on a low-carb diet plan. 30-day washout would be required.\n35. Patient has to have stable weight over the past 3 months (± 5% total body weight). If no weight was recorded in the past 3 months, will have 1 month lead in time for wash out.\n36. Refusal to consent.","80 Years",{"count":344,"type":23},90,[56],"This study is being done to evaluate the effects of a low carbohydrate ketogenic diet (KD) versus a low-fat diet (MD) on exercise tolerance in participants with heart failure with normal pumping function and diabetes or pre-diabetes, or metabolic syndrome, or obesity.",[348],"Heart Failure With Preserved Ejection Fraction",[350,351],"Ketogenic Diet","Heart Failure",{"date":299,"type":36},{"date":354,"type":36},"2023-05-19",{"date":356,"type":23},"2026-08-31",{"name":42,"class":43},{"id":359,"slug":360,"hasResults":12,"nctId":361,"briefTitle":362,"officialTitle":363,"acronym":4,"eligibilityCriteria":364,"healthyVolunteers":12,"sex":87,"minAge":52,"maxAge":4,"enrollmentInfo":365,"targetDuration":4,"studyType":24,"phases":367,"briefSummary":368,"conditions":369,"keywords":371,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":377,"lastUpdatePostDateStruct":378,"startDateStruct":379,"completionDateStruct":381,"leadSponsor":383,"locationsCount":79},"100639414","a-unique-co-designed-family-based-therapy-100639414","NCT07587359","A Unique, Co-Designed Family-Based Therapy","A Unique, Co-Designed Family-Based Therapy for Women With Opioid Use Disorder and Justice-Involvement","Inclusion Criteria for Specialty Treatment Court Participants:\n\n* 18 years of age or older\n* Identify as a woman\n* meet or have met DSM5 criteria for an Opioid Use Disorder (OUD)\n* report current or prior sex trade involvement\n* attending a specialty treatment court \u002F treatment diversion program\n* Identify one family member able to participate\n\nInclusion Criteria for Family Participants\n\n* 18 years of age or older\n* Willing to participate in a hypothetical family intervention\n\nExclusion Criteria for Specialty Treatment Court Participants:\n\n* Under age 18\n* Non-English speaking\n\nExclusion Criteria for Family Participants:\n\n* Under age 18\n* Non-English Speaking",{"count":366,"type":23},120,[56],"The goal of this pilot trial is to evaluate the feasibility and acceptability of an adapted MDFT intervention with women who report prior OUD and sex trade involvement participating in specialty court treatment programs. The main question\\[s\\] the trial aims to answer are:\n\n1. Will the inclusion of the adapted MDFT intervention be feasible among the target population?\n2. Will participant dyads assigned to the adapted intervention perceive the intervention as acceptable and beneficial?\n\nParticipants will be randomly assigned to receive either: 1) the adapted MDFT + TAU; or 2) TAU. Participants will complete baseline and post-intervention assessments.",[370],"Opioid Abuse (Disorder)",[372,373,374,375,376],"opioid use","sex trafficking","sex trade involvement","family intervention","specialty treatment court program","2026-07-21",{"date":330,"type":36},{"date":380,"type":36},"2026-06-14",{"date":382,"type":23},"2028-04-28",{"name":42,"class":43},{"id":385,"slug":386,"hasResults":12,"nctId":387,"briefTitle":388,"officialTitle":389,"acronym":390,"eligibilityCriteria":391,"healthyVolunteers":12,"sex":18,"minAge":52,"maxAge":4,"enrollmentInfo":392,"targetDuration":4,"studyType":24,"phases":394,"briefSummary":395,"conditions":396,"keywords":403,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":377,"lastUpdatePostDateStruct":424,"startDateStruct":425,"completionDateStruct":427,"leadSponsor":429,"locationsCount":79},"100614348","reducing-parental-substance-use-and-enhancing-family-resilience-among-rural-families-through-ohio-start-100614348","NCT07278427","Reducing Parental Substance Use and Enhancing Family Resilience Among Rural Families Through Ohio START","Reducing Parental Substance Use, Improving Child Health Outcomes, and Enhancing Family Resilience Among Rural Families Through Ohio START (Sobriety, Treatment, and Reducing Trauma)","Ohio START","Inclusion Criteria:\n\n* age 18 or older\n* who score 3 or higher on the substance use screening tool (UNCOPE)",{"count":393,"type":23},400,[56],"The goal of this observational study is to learn about the roles played by parental activity spaces and social networks in reducing parental substance use and promoting child and family health outcomes in the context of Ohio START (Sobriety, Treatment, and Reducing Trauma) for families in rural areas. This study will investigate if substance use treatment service referrals and family peer mentoring services provided by Ohio START lead to positive changes in parental activity spaces and social networks, and if these positive changes lead to better child and family outcomes. The main questions it aims to answer are:\n\n* Does having behavioral health services (referred by Ohio START workers) close to where parents spend their time help with substance use recovery and child health?\n* Does peer mentor support through Ohio START help parents build stronger social connections and family resilience, and does this lead to better long-term family health?\n* Do these associations differ in rural areas compared to urban areas?\n\nParticipants will:\n\n* Answer survey questions about their substance use, parenting, child health, and family well-being across three waves (Wave 1: when they enroll in the study, Wave 2: 6-month follow-up, and Wave 3: 12-month follow-up)\n* Share information about places they go regularly (such as work, stores, and healthcare visits)\n* Share information about people in their support network",[397,398,399,400,401,402],"Substance Use Disorder (SUD)","Rural Health","Family Resilience","Child Maltreatment","Child Well-beiing","Substance Use Recovery",[404,405,406,407,408,409,410,411,412,413,414,415,416,417,418,419,390,420,421,422,423],"Substance use disorder","Child abuse and neglect","Rural health","Child welfare services","Low socioeconomic status","Rurality","Longitudinal study","Prospective study","Family resilience","Social network","Activity spaces","Child maltreatment","Parental substance use","Family peer mentors","Social networks","Rural families","Child well-being","Substance use treatment services","Family health","The START model",{"date":330,"type":36},{"date":426,"type":36},"2026-05-21",{"date":428,"type":23},"2030-08-01",{"name":42,"class":43},{"id":431,"slug":432,"hasResults":12,"nctId":433,"briefTitle":434,"officialTitle":435,"acronym":4,"eligibilityCriteria":436,"healthyVolunteers":12,"sex":18,"minAge":235,"maxAge":208,"enrollmentInfo":437,"targetDuration":4,"studyType":24,"phases":438,"briefSummary":440,"conditions":441,"keywords":442,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":377,"lastUpdatePostDateStruct":444,"startDateStruct":445,"completionDateStruct":446,"leadSponsor":448,"locationsCount":79},"100579163","phase-2-a-mechanistic-study-to-assess-a-single-dose-of-cyb003-in-participants-with-depression-and-anxiety-100579163","NCT06820723","A Mechanistic Study to Assess a Single Dose of CYB003 in Participants With Depression and Anxiety","A Randomized, Double-Blind, Placebo-Controlled Mechanistic Study to Assess a Single Oral Dose of CYB003 in Participants With Major Depressive Disorder (MDD) and Moderate to Severe Anxiety","Inclusion Criteria:\n\n* Participant is assigned female or male at birth.\n* Participant is aged between 21 to 65 years, inclusive, at Screening.\n* Participant has a BMI of 18 to 30 kg\u002Fm2, inclusive, at Screening.\n* Participant is ≥60 kg.\n* Participant has a diagnosis of MDD (as defined in the DSM-5 established through a clinician interview that includes the Mini-International Neuropsychiatric Interview)\n* Depression severity moderate to severe based on MADRS score ≥21.\n* Anxiety severity moderate to severe based on GAD-7 ≥10.\n* Inadequate response to current antidepressant medication in current episode of depression.\n* Participant has been on a stable dose (no more than 50% change) of antidepressant medication (SSRI or SNRI) in the last month prior to Screening.\n* Participants capable of producing sperm must use a condom during the trial and for 3 months after their dose of trial medication, if their partner is a person of childbearing potential. In addition, their partner of childbearing potential must use a highly effective method of contraception (i.e., failure rate less than 1% when used consistently and correctly) from dosing until 3 months following dosing.\n* Participants of childbearing potential must agree to use a highly effective method of contraception (i.e., failure rate less than 1% when used consistently and correctly) in combination with use of a condom by a partner who is capable of producing sperm, during the trial and for 3 months after dosing. Such participants must have a negative pregnancy test at Screening and Day 1.\n* Participants of non-childbearing potential who are or were capable of producing eggs (ova) must be postmenopausal or permanently sterile following hysterectomy, bilateral salpingectomy or bilateral oophorectomy. Postmenopausal is defined as spontaneous amenorrhea for at least 12 months, and a serum follicle stimulating hormone (FSH) level in the menopausal range, unless the participant is taking hormone replacement therapy or is using hormonal contraception.\n* Provision of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form.\n\nExclusion Criteria:\n\n* A reduction in the MADRS score of 25% or more between Screening and Baseline.\n* Failure to respond to \\>2 antidepressant treatments given at an adequate dose for an adequate duration during the current episode of depression.\n* Current or previously diagnosis of schizophrenia spectrum or other psychotic disorders, including schizophrenia, schizoaffective disorder, schizotypal disorder, schizophreniform disorder or brief psychotic disorder; current or previous history of bipolar disorder, or current personality disorder (as determined by MINI at Screening).\n* Clinically significant risk of suicidality, as determined through a comprehensive psychiatric interview that incorporates the Columbia Suicide Severity Rating Scale (CSSRS); a score of 4 or higher on the suicidal ideation subscale of C-SSRS (past 6 months) or any suicidal behaviour (lifetime), would be exclusionary.\n* History of substance use disorder within the 12 months, as assessed by a structured clinical interview (Mini International Neuropsychiatric Interview \\[MINI\\], Version 7.0.2) or determined by self-report, or intake of \\>21 units of alcohol weekly, and the inability to refrain from alcohol use from 48 hours before Screening and each scheduled visit until discharge from the study site. One unit is equivalent to a 285 mL glass of full-strength beer or 1 (30 mL) measure of spirits or 1 glass (100 mL) of wine.\n* Currently receiving a monoamine oxidase inhibitor, tricyclic antidepressant, other non-SSRI or non-SNRI antidepressants (e.g. bupropion, mirtazapine, etc), an antipsychotic or a mood stabilizer.\n* Exposure to psilocin, or any other psychedelics, such as ayahuasca, mescaline, LSD or peyote more than 10 times in the last 10 years, or any psychedelic use within 6 months prior to Screening.\n* Use of psychotropic medicine\u002Fsupplement (or medicine\u002Fsupplement that would interact with psilocybin) during the 28 days before dosing. Participants may take a stable chronic dose of antidepressant medication(s) and\u002For sedatives\u002Fhypnotics. The Investigator and study team may review medication on a case-by-case basis to determine if its use would compromise participant safety or interfere with study procedures or data interpretation.\n* Family history of schizophrenia or schizoaffective disorder (first degree relatives), or bipolar disorder type 1 (first degree relatives).\n* Clinically relevant history of abnormal physical health interfering with the study as determined by medical history and physical examinations obtained during Screening as judged by the Investigator (including but not limited to, neurological, endocrine, cardiovascular, respiratory, gastrointestinal \\[including dyspepsia or gastroesophageal reflux disease\\], hepatic, or renal disorder).\n* Participant has a presence or relevant history of any of the following medical conditions: organic brain disorders (e.g., epilepsy, seizure, intracranial hypertension, intracranial bleed and aneurysmal disease, brain tumor or other medical conditions associated with seizures or convulsions).\n* Diagnosis of hypertension or arrhythmia.\n* Clinically relevant abnormal heart rate (resting supine heart rate \\>100 bpm) or blood pressure (resting supine systolic blood pressure (SBP) above 140 mmHg or diastolic blood pressure (DBP) above 90 mmHg) at screening. Screening supine SBP, DBP and heart rate for evaluation will be the average of 3 readings obtained after at least 5 minutes rest. Participants with abnormal vital signs which are out of range and deemed clinically significant by the Investigator at Day 1, following triplicate readings.\n* Presence of clinically significant ECG abnormalities at the Screening visit, as defined by medical judgement.\n* QT interval corrected for heart rate using Fridericia's formula (QTcF) \\>450 msec at Screening, following triplicate ECG readings.\n* Hypothyroidism and\u002For current abnormal thyroid function tests. In case of uncertain or questionable screening thyroid function test results, the TSH test may be repeated once during screening. The TSH test must be reviewed to ensure that it is within normal limits before randomizing a participant into the study.\n* Clinically relevant abnormal laboratory results (including hepatic and renal panels, complete blood count, chemistry panel and urinalysis), 12-lead ECG and vital signs, or physical findings at Screening. In case of uncertain or questionable results, tests performed during Screening may be repeated once to confirm eligibility or judged to be clinically irrelevant.\n* Other eligibility considerations (i.e., participant personal circumstances, behavior, and\u002For any current problem that might interfere with participation or that is incompatible with establishment of rapport or safe exposure to psilocin), as judged by the Investigator.\n* History or clinical evidence of any disease and\u002For existence of any surgical or medical condition which might interfere with the absorption, distribution, metabolism or excretion (ADME) of the study drug.\n* Any other concomitant disease or condition that could interfere with, or for which the treatment might interfere with, the conduct of the study as outlined in this Protocol, or that would, in the opinion of the Investigator, pose an unacceptable risk to the participant in this study.\n* Participant is not fluent in English.\n* Aspartate aminotransferase (AST), alanine transaminase (ALT), gamma-glutamyl transferase (GGT) or total bilirubin levels ≥1.5 x the upper limit of normal (ULN) at Screening. These laboratory evaluations may be repeated once at the discretion of the Investigator. If the repeat test is within the reference range, the participant may be included if the Investigator considers that the previous finding will not introduce additional risk factors.\n* Positive urine test for drugs of abuse or alcohol breath test at Screening or Day 1. A positive test for cannabinoids (e.g., marijuana) at Screening may not exclude a participant if after discussion with and evaluation by the Investigator, the participant agrees not to use any marijuana or other cannabinoid products during the study, and if allowed to participate, the participant must test negative for cannabinoids on Day 1.\n* Participant who consumes excessive amounts of caffeine (e.g., coffee, tea, caffeinated sodas) or (methyl) xanthines (e.g., chocolate) based on the Investigator's determination and discretion.\n* The participant has participated in a clinical study and has received a medication or a new chemical entity within 3 months prior to dosing of current study medication.\n* Known sensitivity to psilocin and\u002For any excipients present in the formulation. Known fructose malabsorption or intolerance, since the orange drink vehicle for study drug contains fructose.\n* Participant is taking or has taken any drugs known to inhibit monoamine oxidase within 28 days prior to study drug administration.\n* Participant is taking or has taken OTC doses of 5-hydroxytryptophan or St John's Wort within 28 days prior to study drug administration.\n* Strenuous exercise within 48 hours prior to each visit, and while at the study site.\n* Participants capable of producing sperm who will not abstain from sperm donation between first dosing and 3 months after final dosing.\n* Participants of childbearing potential who are pregnant, breastfeeding or planning to conceive.",{"count":210,"type":23},[439],"PHASE2","The goal of this study is to learn how psychedelics may help symptoms of depression and anxiety. Participants with major depressive disorder experiencing symptoms of depression and anxiety will receive one dose of either a drug related to psilocybin or a placebo. Assessments include interviews, self-report questionnaires, EEG and fMRI to measure symptoms and brain function.",[216,59,217],[443],"psychedelics",{"date":299,"type":36},{"date":224,"type":23},{"date":447,"type":23},"2028-11",{"name":42,"class":43},{"id":450,"slug":451,"hasResults":12,"nctId":452,"briefTitle":453,"officialTitle":454,"acronym":4,"eligibilityCriteria":455,"healthyVolunteers":12,"sex":18,"minAge":52,"maxAge":4,"enrollmentInfo":456,"targetDuration":4,"studyType":24,"phases":457,"briefSummary":458,"conditions":459,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":377,"lastUpdatePostDateStruct":461,"startDateStruct":462,"completionDateStruct":464,"leadSponsor":466,"locationsCount":79},"100538200","spinal-cord-stimulation-and-small-fiber-peripheral-neuropathy-100538200","NCT06287736","Spinal Cord Stimulation and Small Fiber Peripheral Neuropathy","A Novel Neuromodulation Approach to Target Small Fiber Neuropathy Early in Diabetes and Measure Functional Recovery","Inclusion Criteria:\n\n* Over 18 years old\n* Diagnosis of diabetic peripheral neuropathy refractory to treatment with gabapentin or pregabalin and at least 1 other class of analgesic\n* Diagnosis of medically refractory pain secondary to diabetic neuropathy\n* Presence of pain for 12 months\n* Lower limb pain intensity score ≥4 on a visual analog scale\n* DN4 ≥4\n* Pass pre-operative neuropsychological assessment (surgical group only)\n* Capable of providing informed consent\n\nExclusion Criteria:\n\n* Severe medical comorbidities that, in the opinion of the surgeon, exclude the patient from surgical intervention\n* Spinal disease with severe spinal stenosis or spinal cord compression in the region of the proposed spinal cord stimulator lead placement\n* Coagulopathy that cannot be corrected\n* Unable to discontinue blood thinning medications\n* Hemoglobin A1c level greater than 10\n* Presence of systemic infection\n* Pregnancy",{"count":158,"type":23},[56],"This is a prospective randomized control trial. Participants enrolled into the study will be randomized into one of three groups, two of which are treatment groups and the third is a control group. A time course of measurements before and after spinal cord stimulation (SCS) treatment (where applicable) will assess pain, DPN severity, small fiber nerve activity, and metabolic health markers.",[460],"Diabetic Peripheral Neuropathy",{"date":299,"type":36},{"date":463,"type":36},"2024-04-17",{"date":465,"type":23},"2028-07-03",{"name":42,"class":43},{"id":468,"slug":469,"hasResults":12,"nctId":470,"briefTitle":471,"officialTitle":472,"acronym":4,"eligibilityCriteria":473,"healthyVolunteers":12,"sex":87,"minAge":52,"maxAge":4,"enrollmentInfo":474,"targetDuration":4,"studyType":24,"phases":475,"briefSummary":476,"conditions":477,"keywords":479,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":484,"lastUpdatePostDateStruct":485,"startDateStruct":486,"completionDateStruct":488,"leadSponsor":489,"locationsCount":79},"100648348","using-the-compuflo-cathcheck-system-to-check-epidural-catheter-function-before-tubal-ligation-a-pilot-study-100648348","NCT07720908","Using the CompuFlo® CathCheck™ System to Check Epidural Catheter Function Before Tubal Ligation: A Pilot Study","Assessing Labor Epidural Catheter Dysfunction for Tubal Ligation in Parturients Using CompuFlo® CathCheck™ System: A Pilot Study","Inclusion Criteria\n\n* Age ≥ 18 years\n* Postpartum women electing to undergo tubal ligation with an indwelling labor epidural catheter\n* Ability to provide informed consent in English\n* Vaginal delivery\n\nExclusion Criteria\n\n* Parturients not receiving labor epidural analgesia or receiving an alternative anesthetic technique during labor and delivery\n* Epidural catheter located \\>2 cm from the documented insertion depth at initial placement\n* Planned elective cesarean delivery\n* Chronic pain conditions (e.g., chronic low back pain, sickle cell disease)\n* Chronic opioid use disorder\n* Chronic gabapentin use\n* Uncontrolled mood disorders that, in the investigator's judgment, may interfere with study participation or interpretation of study outcomes\n* Prisoners or incarcerated individuals",{"count":366,"type":23},[56],"This pilot study evaluates the use of the CompuFlo® CathCheck™ System to assess labor epidural catheter function before reactivation for postpartum tubal ligation. The study aims to determine whether this technology can accurately identify functional versus dysfunctional epidural catheters compared with standard clinical assessment methods. Improving catheter assessment may reduce failed epidural reactivation, the need for additional anesthesia techniques, and improve patient safety.",[478],"Anesthesia, Epidural",[480,481,482,483],"Labor epidural catheter","Epidural catheter dysfunction","CompuFlo CathCheck System","Tubal ligation in parturients","2026-07-17",{"date":330,"type":36},{"date":487,"type":36},"2024-12-19",{"date":226,"type":23},{"name":42,"class":43},{"id":491,"slug":492,"hasResults":12,"nctId":493,"briefTitle":494,"officialTitle":495,"acronym":496,"eligibilityCriteria":497,"healthyVolunteers":12,"sex":18,"minAge":52,"maxAge":4,"enrollmentInfo":498,"targetDuration":4,"studyType":24,"phases":500,"briefSummary":501,"conditions":502,"keywords":504,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":484,"lastUpdatePostDateStruct":517,"startDateStruct":518,"completionDateStruct":520,"leadSponsor":522,"locationsCount":79},"100648280","aroma-nt-essential-oils-and-wearable-tens-device-for-chronic-nausea-100648280","NCT07720336","AROMA-NT: Essential Oils and Wearable TENS Device for Chronic Nausea","AROMA-NT: Assessment of the Mechanisms of Action of Inhaled Essential Oils and Wearable TENS Unit Device on Nausea","AROMA-NT","Inclusion Criteria:\n\nAge 18 years or older. Chronic nausea for more than 6 months. Nausea on 3 or more days during the previous week. Severe or very severe nausea. At least moderate anxiety as defined by a Generalized Anxiety Disorder-7 (GAD-7) score of 10 or greater.\n\nAble to read and understand English. Willing and able to complete study procedures and questionnaires\n\nExclusion Criteria:\n\nCurrently receiving treatment for cancer. Decompensated cirrhosis, including cirrhosis with ascites, variceal bleeding, or hepatic encephalopathy.\n\nCurrently receiving dialysis. Gastrointestinal surgery within the previous 3 months. Stroke within the previous 3 months. Currently pregnant (self-reported). Symptoms consistent with carpal tunnel syndrome based on the Kamath-Stothard questionnaire.\n\nInflammation, irritation, infection, or other significant skin disease near the wrist at the intended site of ReliefBand application.\n\nLatex allergy, due to natural rubber latex contained in the ReliefBand wrist strap",{"count":499,"type":23},250,[56],"This study will investigate how two inhaled essential oil products (QueaseEASE and STILL) and a wearable transcutaneous electrical nerve stimulation (TENS) device (ReliefBand) affect chronic nausea and anxiety in adults with longstanding nausea. The goal is to better understand the mechanisms by which these non-prescription therapies may influence nausea, anxiety, sleep, pain, autonomic symptoms, and bowel-related symptoms.\n\nParticipants will first complete a 2-week baseline period during which nausea and other symptoms are assessed through questionnaires. Participants will then use the inhaled essential oil products as needed for 12 weeks while completing symptom surveys. Afterward, participants will use the ReliefBand wearable TENS device as needed for an additional 12 weeks and continue completing surveys. Researchers will compare symptom changes during the intervention periods with baseline measurements to better understand factors that contribute to chronic nausea and how these therapies may provide relief. Up to 250 participants may be enrolled to achieve approximately 100 participants completing both intervention phases",[503,59],"Chronic Nausea",[505,69,506,507,508,509,510,511,512,513,514,515,516],"chronic nausea","aromatherapy","essential oil","inhaled essential oil","transcutaneous Electrical Nerve Stimulation","mechanism of action","autonomic dysfunction","sleep disturbance","stress","pain","bowel symptoms","quality of life",{"date":330,"type":36},{"date":519,"type":36},"2024-05-17",{"date":521,"type":23},"2027-12-31",{"name":42,"class":43},{"id":524,"slug":525,"hasResults":12,"nctId":526,"briefTitle":527,"officialTitle":528,"acronym":529,"eligibilityCriteria":530,"healthyVolunteers":12,"sex":18,"minAge":52,"maxAge":4,"enrollmentInfo":531,"targetDuration":4,"studyType":24,"phases":532,"briefSummary":533,"conditions":534,"keywords":536,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":484,"lastUpdatePostDateStruct":545,"startDateStruct":546,"completionDateStruct":548,"leadSponsor":550,"locationsCount":79},"100648256","evaluating-whether-a-nausea-band-reduces-symptoms-in-those-with-chronic-nausea-vomiting-100648256","NCT07720323","Evaluating Whether a Nausea Band Reduces Symptoms in Those With Chronic Nausea Vomiting","Evaluating the Effect of a WearIng a TENS-device in NausEa Relief (The WINNER Study)","WINNER","Inclusion Criteria:\n\n* Nausea present for more than 2 months. Age 18 years or older. Able to understand English. Receiving care at The Ohio State University. Able to complete online surveys using a smartphone or computer\n\nExclusion Criteria:\n\n* Active treatment for cancer Current treatment for inflammatory bowel disease Cirrhosis End-stage renal disease Prior use of a wearable TENS unit for nausea Abdominal surgery within the previous 3 months Pregnancy (self-reported at enrollment) Current carpal tunnel syndrome Any contraindication to use of the EmeTerm device Inflammation, irritation, infection, ulceration, bleeding, open wounds, or other skin conditions near the wrist where the device is applied Presence of metallic implants in the body Head or facial injury within the previous 3 months Known brain tumor, meningitis, or stroke within the previous 3 months Cardiac pacemaker, implanted defibrillator, or other implanted metallic or electronic device History of seizures",{"count":366,"type":23},[56],"The goal of this clinical trial is to learn whether a wearable transcutaneous electrical nerve stimulation (TENS) device called EmeTerm can help reduce nausea in adults who have had nausea for 2 months or longer and who receive care at The Ohio State University. The study will also evaluate whether use of the device affects other symptoms and aspects of wellbeing, including vomiting, abdominal pain, bloating, constipation, appetite, sleep, mood, stress, fatigue, quality of life, and hope. \\[34\\_Emeterm...rotocol\\_v3 \\| Word\\]\n\nThe main questions it aims to answer are:\n\nDoes using the EmeTerm device reduce the average weekly frequency of moderate to severe nausea compared with symptoms during a baseline observation period? \\[34\\_Emeterm...rotocol\\_v3 \\| Word\\] Does using the EmeTerm device reduce the duration of nausea, frequency of vomiting, and use of anti-nausea medications, and improve other gastrointestinal symptoms, wellbeing, and quality of life? \\[34\\_Emeterm...rotocol\\_v3 \\| Word\\]\n\nThis is a single-arm study. Participants will serve as their own comparison by comparing symptoms during device use with symptoms recorded during the baseline period before using the device. \\[34\\_Emeterm...rotocol\\_v3 \\| Word\\]\n\nParticipants will:\n\nComplete a screening survey and provide electronic informed consent if eligible. \\[34\\_Emeterm...rotocol\\_v3 \\| Word\\] Complete baseline questionnaires and record daily gastrointestinal symptoms for a 2-week baseline period. \\[34\\_Emeterm...rotocol\\_v3 \\| Word\\] Receive an EmeTerm wearable TENS device and instructions for its use. \\[34\\_Emeterm...rotocol\\_v3 \\| Word\\] Use the EmeTerm device for 12 weeks while continuing to record nausea and other gastrointestinal symptoms. \\[34\\_Emeterm...rotocol\\_v3 \\| Word\\] Complete weekly and monthly surveys about symptoms, stress, sleep, appetite, fatigue, quality of life, anxiety, depression, autonomic symptoms, device experience, and any adverse events.",[503,535],"Chronic Nausea and Vomiting Syndrome",[505,537,538,539,540,541,542,516,543,544],"TENS","wearable device","median nerve stimulation","nausea and vomiting","gastroparesis","neuromodulation","vomiting","appetite",{"date":330,"type":36},{"date":547,"type":36},"2023-02-01",{"date":549,"type":23},"2028-06-30",{"name":42,"class":43},{"id":552,"slug":553,"hasResults":12,"nctId":554,"briefTitle":555,"officialTitle":555,"acronym":4,"eligibilityCriteria":556,"healthyVolunteers":12,"sex":87,"minAge":52,"maxAge":4,"enrollmentInfo":557,"targetDuration":4,"studyType":239,"phases":4,"briefSummary":559,"conditions":560,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":484,"lastUpdatePostDateStruct":562,"startDateStruct":564,"completionDateStruct":566,"leadSponsor":568,"locationsCount":79},"100647253","dural-puncture-epidural-dpe-technique-efficacy-and-safety-overview-100647253","NCT07704554","Dural Puncture Epidural (DPE) Technique: Efficacy and Safety Overview.","Inclusion Criteria:\n\n* o Women with a single vertex presentation fetus at term (37-42 weeks) with intact fetal membranes or membrane rupture \\\u003C6 hours previously, who request to have an epidural for labor analgesia and provide written consent for the study.\n\nExclusion Criteria:\n\n* o Patients being treated\u002Fmanaged for chronic pain.\n\n  * Allergies or significant adverse reactions to local anesthetic or opioid medications\n  * Contraindication to labor epidural placement\n  * Patients with history of spine abnormalities or spine surgery.\n  * Prisoners\n  * Clinical signs or symptoms of infection.\n  * Non-English speakers.",{"count":558,"type":23},150,"Neuraxial techniques such as lumbar epidural and combined spinal-epidural (CSE) are the most effective methods for labor analgesia and are associated with high patient satisfaction. However, standard epidurals can have failure rates and may be difficult to reliably confirm correct placement.\n\nThe dural puncture epidural (DPE) technique has been introduced to improve confirmation of epidural placement and potentially enhance analgesia. It involves identifying the epidural space, puncturing the dura with a spinal needle without injecting medication, confirming cerebrospinal fluid flow, and then placing the epidural catheter. While DPE may improve analgesia and drug spread, current evidence is limited and does not clearly demonstrate superiority over standard epidural techniques.\n\nAt The Ohio State Wexner Medical Center, DPE is used routinely for labor epidurals. This observational study evaluates epidural failure rates and anesthesia provider confidence in performing DPE, while also collecting procedural details, patient characteristics, analgesic outcomes, and complications. Provider confidence is assessed using a 3-point scale along with factors influencing performance, and patient outcomes include pain relief, need for rescue dosing, and overall epidural effectiveness.",[561],"Labor Pain",{"date":563,"type":36},"2026-07-20",{"date":565,"type":36},"2024-10-01",{"date":567,"type":23},"2028-01-31",{"name":42,"class":43},{"id":570,"slug":571,"hasResults":12,"nctId":572,"briefTitle":573,"officialTitle":574,"acronym":4,"eligibilityCriteria":575,"healthyVolunteers":12,"sex":18,"minAge":52,"maxAge":208,"enrollmentInfo":576,"targetDuration":4,"studyType":24,"phases":578,"briefSummary":579,"conditions":580,"keywords":582,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":587,"lastUpdatePostDateStruct":588,"startDateStruct":589,"completionDateStruct":590,"leadSponsor":591,"locationsCount":79},"100648173","effect-of-virtual-yoga-in-diabetic-gastroparesis-patients-100648173","NCT07717554","Effect of Virtual Yoga in Diabetic Gastroparesis Patients","The Effect of Virtual Yoga Intervention on Symptom Severity and Quality of Life in Patients With Diabetic Gastroparesis","Inclusion Criteria:\n\n* History of type 1 or type 2 diabetes Gastroparesis defined by documented delayed gastric emptying, assessed by a 4-hour gastric emptying test showing more than 10% retained food in the stomach after 4 hours. This test must have been performed clinically before study enrolment.\n* Experiencing at least moderate Gastroparesis symptoms\n\nExclusion Criteria:\n\n* Patients with severe depression or severe anxiety as assessed by screening questionnaire. Patients with Active inflammatory bowel disease. Participants with abdominal surgeries within the last 3 months. Severe Co-morbidities: Presence of severe comorbid conditions (e.g., advanced cardiovascular or respiratory disease) that could interfere with participation in the yoga intervention. Patients who self-report with current Pregnancy and Breastfeeding\n* Regular yoga practitioners (more than once a week) in the last 6 months. Undergoing current treatment for any cancer.",{"count":577,"type":23},240,[56],"The purpose of this study is to investigate the potential benefits of an online yoga module for patients with gastroparesis. Specifically, the study aims to:\n\n1. Evaluate the Impact of Yoga Practices: Examine whether practicing yoga, including pranayama (breathing techniques), mindfulness meditation, and guided relaxation, can help reduce symptoms of gastroparesis, such as nausea, vomiting, bloating, and abdominal pain.\n2. Assess Psychological Factors: Determine if the yoga intervention can improve associated psychological factors, including mental well-being, sleep quality, and overall quality of life for individuals with gastroparesis.\n3. Provide Evidence-Based Insights: Contribute to the evidence base on the effectiveness of non-pharmacological treatments like yoga in managing gastroparesis, which may offer an additional, accessible management option for patients.",[581],"Diabetic Gastroparesis",[583,584,585,516,586],"yoga","diabetic gastroparesis","virtual yoga","gastroparesis symptom severity","2026-07-16",{"date":377,"type":36},{"date":484,"type":36},{"date":226,"type":23},{"name":42,"class":43},{"id":593,"slug":594,"hasResults":12,"nctId":595,"briefTitle":596,"officialTitle":597,"acronym":4,"eligibilityCriteria":598,"healthyVolunteers":12,"sex":18,"minAge":52,"maxAge":4,"enrollmentInfo":599,"targetDuration":4,"studyType":24,"phases":601,"briefSummary":602,"conditions":603,"keywords":606,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":587,"lastUpdatePostDateStruct":612,"startDateStruct":613,"completionDateStruct":614,"leadSponsor":615,"locationsCount":79},"100648023","virtual-poetry-workshops-to-enhance-patient-well-being-and-reduce-anxiety-100648023","NCT07717541","Virtual Poetry Workshops to Enhance Patient Well Being and Reduce Anxiety","Poetry Workshops to Enhance Patient Well-Being and Reduce Anxiety Levels","Inclusion Criteria:\n\n* • At least 18 years old\n\n  * Ability to provide informed consent\n  * Able to speak and understand English\n  * Able to attend virtual poetry workshops\n  * Willing to share at least 3 poems at the end of the study with the study team\n  * Have access to a high-speed internet connection and smart phone or computer\n  * Willing to participate in group activity if randomized to the facilitated workshops\n  * At least moderate dyspepsia assessed by the Dyspepsia questionnaire (at least one of the following symptoms with moderate or worse severity- nausea, vomiting, early satiety, post prandial fullness AND\n  * At least moderate anxiety or depression assessed by HADS questionnaire. The HADS score has 2 subscores- HADS-A for anxiety and HADS-D for depression. A score of ≥ 21 indicates moderate anxiety and will be required to be eligible for the study.\n\nExclusion Criteria:\n\n* Unable to speak English or participate in virtual sessions\n* Younger than 18 years old",{"count":600,"type":23},80,[56],"This study examines whether participating in poetry workshops can improve emotional well-being among patients with chronic digestive symptoms. Many individuals with long-standing digestive conditions experience distress, anxiety, isolation, and difficulty expressing their emotions in clinical settings. These emotional challenges can negatively affect daily life, relationships, and overall health.\n\nPoetry writing offers a creative and supportive way for participants to explore their feelings, express their experiences, and build emotional resilience. It also allows individuals to focus on aspects of their identity beyond their illness.\n\nThe purpose of this research is to evaluate whether poetry workshops can reduce anxiety, lessen feelings of isolation, and strengthen participants' sense of community and well being.\n\n1\\. Why is this study being done?\n\nThe purpose of this research study is to offer a creative outlet for patients to explore their identity and story, build resilience, and seek hope. This study is being done because we understand that the psychological discomfort that can come upon hearing a diagnosis can lead to increased anxiety levels, negatively impacting a patient's well-being and relationships. Often healthcare practitioners may merely view a patient through the lens of their diagnosis, neglecting other aspects of their identity and humanity. Through reading various poems, crafting their own poems, and sharing their work with their peers, we hope the workshops offer a comforting opportunity for the participants to explore their identities and creativity.",[604,605,59,216],"Dyspepsia","Gastroparesis",[607,69,608,609,541,610,611],"poetry","depression","dyspepsia","virtual","creativity",{"date":377,"type":36},{"date":484,"type":23},{"date":226,"type":23},{"name":42,"class":43},{"id":617,"slug":618,"hasResults":12,"nctId":619,"briefTitle":620,"officialTitle":621,"acronym":4,"eligibilityCriteria":622,"healthyVolunteers":12,"sex":18,"minAge":623,"maxAge":624,"enrollmentInfo":625,"targetDuration":4,"studyType":24,"phases":627,"briefSummary":628,"conditions":629,"keywords":632,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":587,"lastUpdatePostDateStruct":638,"startDateStruct":639,"completionDateStruct":641,"leadSponsor":643,"locationsCount":79},"100630651","phase-2-metric-optimized-spectacle-prescriptions-for-children-with-down-syndrome-100630651","NCT07490444","Metric-Optimized Spectacle Prescriptions for Children With Down Syndrome","Metric-derived Corrections Versus Clinically-derived Corrections for Children With Down Syndrome","Inclusion Criteria:\n\n* Down syndrome\n* Age 5 to 12 years\n* Ability to sit for study measures\n* Able to be dilated\n\nExclusion Criteria:\n\n* Nystagmus\n* History of Ocular or Refractive Surgery\n* Corneal or lenticular opacities\n* Ocular disease\n* Anisometropic or strabismic amblyopia\n* Contact allergy to aluminum","5 Years","12 Years",{"count":626,"type":23},24,[439],"This study seeks to determine whether glasses prescriptions determined from computer analysis of detailed images of the eyes provide better vision outcomes for children with Down syndrome than prescriptions determined using routine clinical methods.",[630,631],"Refractive Error Correction","Visual Acuity",[633,634,635,636,637],"Down syndrome","Children","Glasses","Spectacles","Vision",{"date":563,"type":36},{"date":640,"type":36},"2026-07-13",{"date":642,"type":23},"2028-05-01",{"name":42,"class":43},{"id":645,"slug":646,"hasResults":12,"nctId":647,"briefTitle":648,"officialTitle":649,"acronym":4,"eligibilityCriteria":650,"healthyVolunteers":12,"sex":18,"minAge":52,"maxAge":4,"enrollmentInfo":651,"targetDuration":4,"studyType":24,"phases":653,"briefSummary":654,"conditions":655,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":657,"lastUpdatePostDateStruct":658,"startDateStruct":659,"completionDateStruct":661,"leadSponsor":663,"locationsCount":664},"100647952","visionway-accessibility-100647952","NCT07713979","VisionWay Accessibility","VisionWay: Accessibility-Aware Path Selection for Wayfinding","Inclusion Criteria:\n\n* At least 18 years old\n* Able to provide informed consent\n* Vision worse than 20\u002F200, encompassing PVI with severe and profound impairment as well as total blindness.\n\nGroup 1 Inclusion:\n\n\\- PVI meeting general inclusion criteria and without mobility aids\n\nGroup 2 Inclusion:\n\n\\- PVI meeting general inclusion criteria and who use a cane as a mobility aid\n\nGroup 3 Inclusion:\n\n\\- PVI meeting general inclusion criteria and who use guide dogs.\n\nExclusion Criteria:\n\n* Conditions that prevent safe ambulation that include, but are not limited to, neuromuscular disorder, post-operative state (such as orthopedic surgeries or cardiac surgeries), balance issues, history of falls in the last 6 months, or at the discretion of the investigator.\n* Use of walker or wheelchair",{"count":652,"type":23},100,[56],"The challenge of outdoor wayfinding, critical for People with Visual Impairments (PVI), consists in helping users safely walk to a pre-determined nearby destination. The main focus of existing solutions from research and industry is to leverage the user's smartphone to receive safe moving directions either from a remote operator or smart app. However, multiple paths may exist to connect users with their destination, each one with unique characteristics in terms of accessibility and safety. Unfortunately, little to no attention has been paid in helping PVI decide, before even starting to walk, which path to take based on their accessibility. Thus, a barrier identified is that the followed path may not be accessible because sidewalk features such as potholes, uncontrolled crossing, interrupted sidewalks, and objects are not known in advance. The investigators' goal is to develop a mobile live, local, outside map framework called VisionWay, customized for PVI-user as a wayfinding tool to analyze, before starting to walk, the accessibility of candidate paths and choose one to the destination.",[656],"Persons With Visual Disabilities","2026-07-14",{"date":563,"type":36},{"date":660,"type":36},"2026-02-26",{"date":662,"type":23},"2027-09-01",{"name":42,"class":43},2,{"id":666,"slug":667,"hasResults":12,"nctId":668,"briefTitle":669,"officialTitle":670,"acronym":4,"eligibilityCriteria":671,"healthyVolunteers":12,"sex":87,"minAge":52,"maxAge":4,"enrollmentInfo":672,"targetDuration":4,"studyType":24,"phases":674,"briefSummary":675,"conditions":676,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":657,"lastUpdatePostDateStruct":678,"startDateStruct":679,"completionDateStruct":681,"leadSponsor":683,"locationsCount":79},"100645877","phase-2-lidocaine-patch-vs-intradermal-lidocaine-for-epidural-needle-insertion-pain-100645877","NCT07700108","Lidocaine Patch vs Intradermal Lidocaine for Epidural Needle Insertion Pain","Prospective, Single-Center, Randomized, Double-Blind Clinical Trial Evaluating Pain During Epidural Tuohy Needle Insertion After 4% Lidocaine Patch or Intradermal Lidocaine Injection in Parturient Women Requesting Epidural Analgesia","Inclusion Criteria:\n\nAge 18 years or older Parturient women requesting neuraxial anesthesia\u002Fanalgesia (epidural or combined spinal-epidural) for vaginal or cesarean delivery Ability to provide informed consent in English\n\nExclusion Criteria:\n\nLess than 30 minutes of lidocaine patch placement prior to epidural placement Administration of opioids within 4 hours before study enrollment Intravenous magnesium sulfate administration within the previous 24 hours Diabetes mellitus (Type 1 or Type 2) Neurocardiogenic signs or symptoms (e.g., dizziness, lightheadedness, bradycardia, or syncope) during intravenous cannulation Cervical dilation greater than 6 cm (if in labor) Spinal anesthesia Chronic pain condition Opioid use disorder Intrauterine fetal demise Prisoner status",{"count":673,"type":23},135,[439],"Needle phobia is a barrier for receiving appropriate care during pregnancy and can lead to complications of the mother and fetus that could easily be avoided. Needle phobia can affect routine prenatal care, increase the demand for general anesthesia during c-section, and increase post-op pain. During epidural placement, providers use local anesthetic in various methods to numb the area where the needle will be inserted. Pain from these anesthetic administrations can increase needle phobia and their side effects.\n\nOne use of local anesthetic is the lidocaine patch, and studies have shown it is effective in reducing pain level in patients \\[6, Firmani\\]. The transdermal lidocaine patch may lower the physical pain and mental effects of needle phobia in pregnant women and lower the side effects from that. Although lidocaine patch may take more time to numb the skin, a high number of expecting mothers will not require an epidural for labor analgesia right away. Therefore, administration of lidocaine patch might be an effective alternative.\n\nPregnant women needing epidural placement will be randomized into three groups, the lidocaine patch group, intradermal anesthetic group, or use of both to determine the effectiveness of the lidocaine patch compared to the intradermal administration.",[677],"Needle Phobia",{"date":587,"type":36},{"date":680,"type":36},"2026-06-29",{"date":682,"type":23},"2029-01-31",{"name":42,"class":43},""]